- Home
- SEER vs CLNN Comparison
SEER vs CLNN Comparison
Compare SEER & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | CLNN |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 120.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEER | CLNN |
|---|---|---|
| Price | $1.83 | $6.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 156.8K | ★ 315.7K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,376,999.00 | $214,000.00 |
| Revenue This Year | $22.37 | N/A |
| Revenue Next Year | $30.00 | $87.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $1.62 | $2.28 |
| 52 Week High | $2.59 | $13.50 |
Technical Indicators
Market Signals| Indicator | SEER | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 35.91 |
| Support Level | $1.85 | $5.42 |
| Resistance Level | $2.02 | $9.92 |
| Average True Range (ATR) | 0.08 | 1.03 |
| MACD | -0.00 | -0.43 |
| Stochastic Oscillator | 7.32 | 14.94 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.